Who are TR-701 FA's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Sivextro 200 milligrams Oral Tablet, Synthomycine 5%, Linezolid (LZD), Tedizolid IV, Tedizolid PO, Linezolid Injectable Product.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/tr-701-fa.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

TR-701 FA — Competitive Intelligence Brief

TR-701 FA (TR-701 FA) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Oxazolidinone antibiotic. Area: Infectious Disease.

phase 3 Oxazolidinone antibiotic Bacterial 70S ribosome Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

TR-701 FA (TR-701 FA) — Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA). TR-701 FA is a prodrug of TR-700 that inhibits bacterial protein synthesis by binding to the bacterial ribosome.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
TR-701 FA TARGET	TR-701 FA	Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)	phase 3	Oxazolidinone antibiotic	Bacterial 70S ribosome
Sivextro 200 milligrams Oral Tablet	Sivextro 200 milligrams Oral Tablet	Fundacion Clinic per a la Recerca Biomédica	marketed	Oxazolidinone antibiotic	Bacterial 70S ribosome (peptidyl transferase center)
Synthomycine 5%	Synthomycine 5%	Barzilai Medical Center	marketed	Broad-spectrum antibiotic (chloramphenicol)	Bacterial 70S ribosome (peptidyl transferase)
Linezolid (LZD)	Linezolid (LZD)	Wuhan Pulmonary Hospital	marketed	Oxazolidinone antibiotic	Bacterial 50S ribosomal subunit (23S rRNA)
Tedizolid IV	Tedizolid IV	University of Southern California	marketed	Oxazolidinone antibiotic	Bacterial 50S ribosomal subunit
Tedizolid PO	Tedizolid PO	University of Southern California	marketed	Oxazolidinone antibiotic	Bacterial 50S ribosomal subunit
Linezolid Injectable Product	Linezolid Injectable Product	Fundacion Clinic per a la Recerca Biomédica	marketed	Oxazolidinone antibiotic	Bacterial 50S ribosomal subunit (23S rRNA)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Oxazolidinone antibiotic class)

Fundacion Clinic per a la Recerca Biomédica · 2 drugs in this class
University of Southern California · 2 drugs in this class
Arpida AG · 2 drugs in this class
Pfizer · 1 drug in this class
Shenzhen Third People's Hospital · 1 drug in this class
Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · 1 drug in this class
Wuhan Pulmonary Hospital · 1 drug in this class
Clinica Universidad de Navarra, Universidad de Navarra · 1 drug in this class
Merck Sharp & Dohme LLC · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). TR-701 FA — Competitive Intelligence Brief. https://druglandscape.com/ci/tr-701-fa. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab